IFNB1 and COVID-19: Our finding that treatment with IFN-β plus remdesivir may be more effective than IFN-β alone as a means to treat betacoronavirus infections correlates well with a previous study, which showed that early cotreatment with IFN-β plus remdesivir was more effective than remdesivir alone in alleviating symptoms and in shortening viral shedding and hospitalization in high-risk COVID-19 patients (Tam et al, 2022).